---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-017579"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:08:58.650477+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics reports Q1 2023 net loss of $5.6M; VYN201 Phase 1b data expected Q3 2023

## Summary
- Q1 2023 GAAP net loss $5.6M vs net income $4.7M in Q1 2022; loss from continuing ops improved to $5.6M from $8.7M.
- Topline 16-week data for all three cohorts of VYN201 Phase 1b trial in vitiligo expected in Q3 2023.
- Lead development candidate selected for VYN202 oral BD2-selective BET inhibitor; IND filing targeted by year-end 2023.
- Positive safety and PK data from VYN201 Phase 1a; no serious adverse events or dose adjustments.
- Preclinical data for inhaled VYN201 in IPF model showed anti-inflammatory and anti-fibrotic effects.

## SEC filing metadata
- accession: 0001628280-23-017579
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/0001628280-23-017579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/mnlo-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-017579
- JSON: https://secwatch.observer/filing/0001628280-23-017579.json
- Plain text: https://secwatch.observer/filing/0001628280-23-017579.txt

## Key facts
- Earnings Releases
  VYNE Therapeutics Inc. reported the three months ended March 31, 2023 results: net income $ (5,622).
  - Period: the three months ended March 31, 2023
  - Net income: $ (5,622)
  - Result: reported results
  source text: 1 Financial Performance (in thousands) Three Months Ended March 31 2023 2022 Loss from continuing operations (GAAP) $ (5,612) $ (8,694) Adjusted loss from continuing operations (non-GAAP)* $ (4,756) $ (7,449) Net (loss) income (GAAP) $ (5,622) $ 4,670 Adjusted net (loss) income (non-GAAP)* $ (4,766) $ 5,563 *See "
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/0001628280-23-017579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.